GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

ClinicalTrials.gov ID

NCT05356104

Lead Sponsor

Chinese University of Hong KongOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

110Estimated

Last Update Posted

Jun 5, 2026Actual

Start Date

May 25, 2022Actual

Primary Completion Date

May 2027Estimated

Completion Date

Dec 2027Estimated

Official Title

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) - A Pilot Study

Brief Summary

Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials.

The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated.

Investigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.

Detailed Description

In this single-center, open-label (assessor blinded), randomized controlled study, 110 patients with cSVD of Age-Related White Matter Changes Scale of 2 or 3 will be randomized into "treatment arm" with GLP-1R agonist and standard medical therapy, and "control" arm with standard medical therapy alone in a 1:1 ratio. In this 78 weeks pilot study, investigators shall evaluate the tolerability and safety profile of GLP-1R agonist in SVD patients, together with changes in clinical, imaging and sonographic parameters.

Clinical and biochemical measures will be assessed at baseline, 12 weeks, 26 weeks and 52 weeks. Transcranial Doppler Ultrasound (TCD) will be performed at baseline, 12 weeks, 26 weeks, 52 weeks and 78 weeks. MRI will be performed at baseline and 78 weeks

• Cerebral Small Vessel Disease

• GLP-1 receptor agonist

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Chinese ethnicity;
2. Age 55 to 80 years old;
3. Age-Related White Matter Change (ARWMC) Scale of 2 or early 3 in FLAIR MRI;
4. Modified Functional Ambulation Classification 5 or above;
5. Montreal Cognitive Assessment (MoCA) score < 25;
6. Both diabetic and non-diabetic patient are eligible;
7. Patient who understands the purpose and requirements of the study, and able to provide an informed consent;

Exclusion Criteria:

1. Dementia or MoCA score lower than 2nd percentile of the age and education adjusted cutoff ;
2. Cerebral white matter changes unrelated to neurodegenerative, e.g. CADASIL, X-linked adrenoleukodystrophy, metabolic diseases, multiple sclerosis, etc.;
3. Contraindication to GLP-1R agonist, including thyroid carcinoma, pancreatic pathology, proliferative retinopathy, hypersensitivity to GLP-1R agonist and history of family history of multiple endocrine neoplasia;
4. BMI <18.5kg/m2;
5. Contraindication to proposed imaging, e.g. chronic kidney disease (KDNIGO) stage 4 or above, acute kidney injury, hypersensitivity to gadolinium-based contrast, non-MRI conditional implants or prosthesis;
6. Medical condition that would not allow the patient to adhere to the protocol or complete the study.;
7. Patient with established neurodegenerative disorders (e.g. Parkinson's Disease, Alzheimer's Disease, etc.);
8. Pregnancy.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

Chinese University of Hong KongOTHER

Collaborators

First Affiliated Hospital of Wenzhou Medical UniversityOTHER

bonaventureip@cuhk.edu.hk852-28902002

• Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

  NCT07282041

  RecruitingInterventionalPhase 2Phase 3Updated Dec 23, 2025
• Songling Xuemaikang Capsules for Cerebral Small Vessel Disease

  NCT07271732

  Not yet recruitingInterventionalNot ApplicableUpdated Dec 9, 2025
• Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease

  NCT06643013

  RecruitingInterventionalNot ApplicableUpdated Oct 15, 2024
• GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis

  NCT07251556

  Not yet recruitingInterventionalPhase 4Updated Dec 2, 2025
• Cardiovascular Effects of GLP-1 Receptor Activation

  NCT03101930

  CompletedInterventionalPhase 4Updated Oct 18, 2022
• The Microvascular Function of GLP-1 and Its Analogues

  NCT01677104

  CompletedInterventionalNot ApplicableUpdated Apr 13, 2017